Search Menu
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information
Search Scholarly Publications

Title: Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging

Abstract

Importance: Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear. Objective: To examine the prognostic accuracy of baseline fluorine 18 (18F)-flortaucipir and [18F]RO948 (tau) PET in individuals across the Alzheimer disease (AD) clinical spectrum and to perform a head-to-head comparison against established magnetic resonance imaging (MRI) and amyloid PET markers. Design, setting, and participants: This prognostic study collected data from 8 cohorts in South Korea, Sweden, and the US from June 1, 2014, to February 28, 2021, with a mean (SD) follow-up of 1.9 (0.8) years. A total of 1431 participants were recruited from memory clinics, clinical trials, or cohort studies; 673 were cognitively unimpaired (CU group; 253 [37.6%] positive for amyloid-β [Aβ]), 443 had mild cognitive impairment (MCI group; 271 [61.2%] positive for Aβ), and 315 had a clinical diagnosis of AD dementia (315 [100%] positive for Aβ). Exposures: [18F]Flortaucipir PET in the discovery cohort (n = 1135) or [18F]RO948 PET in the replication cohort (n = 296), T1-weighted MRI (n = 1431), and amyloid PET (n = 1329) at baseline and repeated Mini-Mental State Examination (MMSE) evaluation. Main outcomes and measures: Baseline [18F]flortaucipir/[18F]RO948more » PET retention within a temporal region of interest, MRI-based AD-signature cortical thickness, and amyloid PET Centiloids were used to predict changes in MMSE using linear mixed-effects models adjusted for age, sex, education, and cohort. Mediation/interaction analyses tested whether associations between baseline tau PET and cognitive change were mediated by baseline MRI measures and whether age, sex, and APOE genotype modified these associations. Results: Among 1431 participants, the mean (SD) age was 71.2 (8.8) years; 751 (52.5%) were male. Findings for [18F]flortaucipir PET predicted longitudinal changes in MMSE, and effect sizes were stronger than for AD-signature cortical thickness and amyloid PET across all participants (R2, 0.35 [tau PET] vs 0.24 [MRI] vs 0.17 [amyloid PET]; P < .001, bootstrapped for difference) in the Aβ-positive MCI group (R2, 0.25 [tau PET] vs 0.15 [MRI] vs 0.07 [amyloid PET]; P < .001, bootstrapped for difference) and in the Aβ-positive CU group (R2, 0.16 [tau PET] vs 0.08 [MRI] vs 0.08 [amyloid PET]; P < .001, bootstrapped for difference). These findings were replicated in the [18F]RO948 PET cohort. MRI mediated the association between [18F]flortaucipir PET and MMSE in the groups with AD dementia (33.4% [95% CI, 15.5%-60.0%] of the total effect) and Aβ-positive MCI (13.6% [95% CI, 0.0%-28.0%] of the total effect), but not the Aβ-positive CU group (3.7% [95% CI, -17.5% to 39.0%]; P = .71). Age (t = -2.28; P = .02), but not sex (t = 0.92; P = .36) or APOE genotype (t = 1.06; P = .29) modified the association between baseline [18F]flortaucipir PET and cognitive change, such that older individuals showed faster cognitive decline at similar tau PET levels. Conclusions and relevance: The findings of this prognostic study suggest that tau PET is a promising tool for predicting cognitive change that is superior to amyloid PET and MRI and may support the prognostic process in preclinical and prodromal stages of AD.« less

Authors:
 [1];  [2];  [3];  [4];  [2];  [2];  [2];  [5];  [6];  [7];  [8];  [9];  [10];  [11];  [11];  [11];  [11];  [11];  [11];  [12] more »;  [13];  [13];  [14];  [14];  [15];  [16];  [17];  [7] « less
+ Show Author Affiliations
  1. Lund Univ. (Sweden). Clinical Memory Research Unit; Vrije Univ., Amsterdam (Netherlands). Amsterdam University Medical Center. Dept. of Neurology. Alzheimer Center Amsterdam
  2. Lund Univ. (Sweden). Clinical Memory Research Unit
  3. Lund Univ. (Sweden). Clinical Memory Research Unit; Skåne Univ. Hospital, Lund (Sweden). Dept. of Neurology; Lund Univ. (Sweden). Wallenberg Centre for Molecular Medicine
  4. Vrije Univ., Amsterdam (Netherlands). Amsterdam University Medical Center. Dept. of Neurology. Alzheimer Center Amsterdam
  5. Skåne Univ. Hospital, Lund (Sweden). Dept. of Radiation Physics
  6. Skåne Univ. Hospital, Lund (Sweden). Dept. of Clinical Physiology and Nuclear Medicine
  7. Lund Univ. (Sweden). Clinical Memory Research Unit; Skåne University Hospital, Malmö (Sweden). Memory Clinic
  8. Yonsei Univ., Seoul (Korea, Republic of). College of Medicine. Gangnam Severance Hospital. Dept. of Neurology
  9. Yonsei Univ., Seoul (Korea, Republic of). College of Medicine. Gangnam Severance Hospital. Dept. of Nuclear Medicine
  10. Yonsei Univ., Seoul (Korea, Republic of). College of Medicine. Gangnam Severance Hospital. Dept. of Nuclear Medicine; Korea Inst. Radiological and Medical Sciences, Seoul (Korea, Republic of). Division of Applied Radiological Imaging
  11. Univ. of California, San Francisco, CA (United States). Dept. of Neurology, Memory and Aging Center
  12. Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
  13. F. Hoffmann–La Roche Ltd, Basel (Switzerland)
  14. Avid Radiopharmaceuticals, Philadelphia, PA (United States)
  15. Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States); Univ. of California, Berkeley, CA (United States). Helen Wills Neuroscience Inst.
  16. Yonsei Univ., Seoul (Korea, Republic of). College of Medicine. Gangnam Severance Hospital. Dept. of Neurology
  17. Univ. of California, San Francisco, CA (United States). Dept. of Neurology, Memory and Aging Center; Univ. of California, San Francisco, CA (United States). Dept. of Radiology and Biomedical Imaging; Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States). Molecular Biophysics and Integrated Bioimaging Division; Associate Editor, JAMA Neurology
Publication Date:
Sponsoring Org.:
USDOE Office of Science (SC), Biological and Environmental Research (BER). Biological Systems Science Division
OSTI Identifier:
1815926
Grant/Contract Number:  
AC02-05CH11231
Resource Type:
Accepted Manuscript
Journal Name:
JAMA Neurology
Additional Journal Information:
Journal Volume: 78; Journal Issue: 8; Journal ID: ISSN 2168-6149
Publisher:
American Medical Association
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Ossenkoppele, Rik, Smith, Ruben, Mattsson-Carlgren, Niklas, Groot, Colin, Leuzy, Antoine, Strandberg, Olof, Palmqvist, Sebastian, Olsson, Tomas, Jögi, Jonas, Stormrud, Erik, Cho, Hanna, Ryu, Young Hoon, Choi, Jae Yong, Boxer, Adam L., Gorno-Tempini, Maria L., Miller, Bruce L., Soleimani-Meigooni, David, Iaccarino, Leonardo, La Joie, Renaud, Baker, Suzanne, Borroni, Edilio, Klein, Gregory, Pontecorvo, Michael J., Devous, Michael D., Jagust, William J., Lyoo, Chul Hyoung, Rabinovici, Gil D., and Hansson, Oskar. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. United States: N. p., 2021. Web. doi:10.1001/jamaneurol.2021.1858.
Copy to clipboard
Ossenkoppele, Rik, Smith, Ruben, Mattsson-Carlgren, Niklas, Groot, Colin, Leuzy, Antoine, Strandberg, Olof, Palmqvist, Sebastian, Olsson, Tomas, Jögi, Jonas, Stormrud, Erik, Cho, Hanna, Ryu, Young Hoon, Choi, Jae Yong, Boxer, Adam L., Gorno-Tempini, Maria L., Miller, Bruce L., Soleimani-Meigooni, David, Iaccarino, Leonardo, La Joie, Renaud, Baker, Suzanne, Borroni, Edilio, Klein, Gregory, Pontecorvo, Michael J., Devous, Michael D., Jagust, William J., Lyoo, Chul Hyoung, Rabinovici, Gil D., & Hansson, Oskar. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. United States. https://doi.org/10.1001/jamaneurol.2021.1858
Copy to clipboard
Ossenkoppele, Rik, Smith, Ruben, Mattsson-Carlgren, Niklas, Groot, Colin, Leuzy, Antoine, Strandberg, Olof, Palmqvist, Sebastian, Olsson, Tomas, Jögi, Jonas, Stormrud, Erik, Cho, Hanna, Ryu, Young Hoon, Choi, Jae Yong, Boxer, Adam L., Gorno-Tempini, Maria L., Miller, Bruce L., Soleimani-Meigooni, David, Iaccarino, Leonardo, La Joie, Renaud, Baker, Suzanne, Borroni, Edilio, Klein, Gregory, Pontecorvo, Michael J., Devous, Michael D., Jagust, William J., Lyoo, Chul Hyoung, Rabinovici, Gil D., and Hansson, Oskar. Mon . "Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging". United States. https://doi.org/10.1001/jamaneurol.2021.1858. https://www.osti.gov/servlets/purl/1815926.
Copy to clipboard
@article{osti_1815926,
title = {Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging},
author = {Ossenkoppele, Rik and Smith, Ruben and Mattsson-Carlgren, Niklas and Groot, Colin and Leuzy, Antoine and Strandberg, Olof and Palmqvist, Sebastian and Olsson, Tomas and Jögi, Jonas and Stormrud, Erik and Cho, Hanna and Ryu, Young Hoon and Choi, Jae Yong and Boxer, Adam L. and Gorno-Tempini, Maria L. and Miller, Bruce L. and Soleimani-Meigooni, David and Iaccarino, Leonardo and La Joie, Renaud and Baker, Suzanne and Borroni, Edilio and Klein, Gregory and Pontecorvo, Michael J. and Devous, Michael D. and Jagust, William J. and Lyoo, Chul Hyoung and Rabinovici, Gil D. and Hansson, Oskar},
abstractNote = {Importance: Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear. Objective: To examine the prognostic accuracy of baseline fluorine 18 (18F)-flortaucipir and [18F]RO948 (tau) PET in individuals across the Alzheimer disease (AD) clinical spectrum and to perform a head-to-head comparison against established magnetic resonance imaging (MRI) and amyloid PET markers. Design, setting, and participants: This prognostic study collected data from 8 cohorts in South Korea, Sweden, and the US from June 1, 2014, to February 28, 2021, with a mean (SD) follow-up of 1.9 (0.8) years. A total of 1431 participants were recruited from memory clinics, clinical trials, or cohort studies; 673 were cognitively unimpaired (CU group; 253 [37.6%] positive for amyloid-β [Aβ]), 443 had mild cognitive impairment (MCI group; 271 [61.2%] positive for Aβ), and 315 had a clinical diagnosis of AD dementia (315 [100%] positive for Aβ). Exposures: [18F]Flortaucipir PET in the discovery cohort (n = 1135) or [18F]RO948 PET in the replication cohort (n = 296), T1-weighted MRI (n = 1431), and amyloid PET (n = 1329) at baseline and repeated Mini-Mental State Examination (MMSE) evaluation. Main outcomes and measures: Baseline [18F]flortaucipir/[18F]RO948 PET retention within a temporal region of interest, MRI-based AD-signature cortical thickness, and amyloid PET Centiloids were used to predict changes in MMSE using linear mixed-effects models adjusted for age, sex, education, and cohort. Mediation/interaction analyses tested whether associations between baseline tau PET and cognitive change were mediated by baseline MRI measures and whether age, sex, and APOE genotype modified these associations. Results: Among 1431 participants, the mean (SD) age was 71.2 (8.8) years; 751 (52.5%) were male. Findings for [18F]flortaucipir PET predicted longitudinal changes in MMSE, and effect sizes were stronger than for AD-signature cortical thickness and amyloid PET across all participants (R2, 0.35 [tau PET] vs 0.24 [MRI] vs 0.17 [amyloid PET]; P < .001, bootstrapped for difference) in the Aβ-positive MCI group (R2, 0.25 [tau PET] vs 0.15 [MRI] vs 0.07 [amyloid PET]; P < .001, bootstrapped for difference) and in the Aβ-positive CU group (R2, 0.16 [tau PET] vs 0.08 [MRI] vs 0.08 [amyloid PET]; P < .001, bootstrapped for difference). These findings were replicated in the [18F]RO948 PET cohort. MRI mediated the association between [18F]flortaucipir PET and MMSE in the groups with AD dementia (33.4% [95% CI, 15.5%-60.0%] of the total effect) and Aβ-positive MCI (13.6% [95% CI, 0.0%-28.0%] of the total effect), but not the Aβ-positive CU group (3.7% [95% CI, -17.5% to 39.0%]; P = .71). Age (t = -2.28; P = .02), but not sex (t = 0.92; P = .36) or APOE genotype (t = 1.06; P = .29) modified the association between baseline [18F]flortaucipir PET and cognitive change, such that older individuals showed faster cognitive decline at similar tau PET levels. Conclusions and relevance: The findings of this prognostic study suggest that tau PET is a promising tool for predicting cognitive change that is superior to amyloid PET and MRI and may support the prognostic process in preclinical and prodromal stages of AD.},
doi = {10.1001/jamaneurol.2021.1858},
journal = {JAMA Neurology},
number = 8,
volume = 78,
place = {United States},
year = {Mon Jun 28 00:00:00 EDT 2021},
month = {Mon Jun 28 00:00:00 EDT 2021}
}
Copy to clipboard
Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
https://doi.org/10.1001/jamaneurol.2021.1858
Copyright Statement
Other availability
Search WorldCat Search WorldCat to find libraries that may hold this journal
Save / Share:
Export Metadata
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.

Works referenced in this record:

Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative
journal, July 2015

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
journal, December 2020

  • Smith, Ruben; Strandberg, Olof; Mattsson-Carlgren, Niklas
  • Brain, Vol. 143, Issue 12
  • DOI: 10.1093/brain/awaa327

Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET
journal, January 2020

  • La Joie, Renaud; Visani, Adrienne V.; Baker, Suzanne L.
  • Science Translational Medicine, Vol. 12, Issue 524
  • DOI: 10.1126/scitranslmed.aau5732

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
journal, April 2019

  • Pontecorvo, Michael J.; Devous, Michael D.; Kennedy, Ian
  • Brain, Vol. 142, Issue 6
  • DOI: 10.1093/brain/awz090

Discriminative Accuracy of [ 18 F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders
journal, September 2018

Whole Brain Segmentation
journal, January 2002

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
journal, October 2014

Tau PET in Alzheimer disease and mild cognitive impairment
journal, June 2016

Tau‐positron emission tomography correlates with neuropathology findings
journal, January 2020

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
journal, March 2016

  • Ossenkoppele, Rik; Schonhaut, Daniel R.; Schöll, Michael
  • Brain, Vol. 139, Issue 5
  • DOI: 10.1093/brain/aww027

Donanemab in Early Alzheimer’s Disease
journal, May 2021

  • Mintun, Mark A.; Lo, Albert C.; Duggan Evans, Cynthia
  • New England Journal of Medicine, Vol. 384, Issue 18
  • DOI: 10.1056/NEJMoa2100708

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
journal, May 2012

  • Nelson, Peter T.; Alafuzoff, Irina; Bigio, Eileen H.
  • Journal of Neuropathology & Experimental Neurology, Vol. 71, Issue 5
  • DOI: 10.1097/NEN.0b013e31825018f7

In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment
journal, June 2020

Longitudinal neuroimaging biomarkers differ across Alzheimer’s disease phenotypes
journal, June 2020

  • Sintini, Irene; Graff-Radford, Jonathan; Senjem, Matthew L.
  • Brain, Vol. 143, Issue 7
  • DOI: 10.1093/brain/awaa155

Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL
journal, December 2018

Defining imaging biomarker cut points for brain aging and Alzheimer's disease
journal, March 2017

  • Jack, Clifford R.; Wiste, Heather J.; Weigand, Stephen D.
  • Alzheimer's & Dementia, Vol. 13, Issue 3
  • DOI: 10.1016/j.jalz.2016.08.005

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
journal, May 2015

APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review
journal, November 2020

  • Emrani, Sheina; Arain, Hirra A.; DeMarshall, Cassandra
  • Alzheimer's Research & Therapy, Vol. 12, Issue 1
  • DOI: 10.1186/s13195-020-00712-4

Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline: Tau, Amyloid, FDG, and Memory in Normal Aging
journal, April 2017

  • Hanseeuw, Bernard J.; Betensky, Rebecca A.; Schultz, Aaron P.
  • Annals of Neurology, Vol. 81, Issue 4
  • DOI: 10.1002/ana.24910

Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia
journal, June 2019

  • Jack, Clifford R.; Wiste, Heather J.; Therneau, Terry M.
  • JAMA, Vol. 321, Issue 23
  • DOI: 10.1001/jama.2019.7437

Tau pathology and neurodegeneration
journal, June 2013

Tau PET imaging in neurodegenerative tauopathies—still a challenge
journal, January 2019

  • Leuzy, Antoine; Chiotis, Konstantinos; Lemoine, Laetitia
  • Molecular Psychiatry, Vol. 24, Issue 8
  • DOI: 10.1038/s41380-018-0342-8

Longitudinal tau PET in ageing and Alzheimer’s disease
journal, March 2018

  • Jack, Clifford R.; Wiste, Heather J.; Schwarz, Christopher G.
  • Brain, Vol. 141, Issue 5
  • DOI: 10.1093/brain/awy059

Alzheimer's disease
journal, April 2021

18F-MK-6240 PET for early and late detection of neurofibrillary tangles
journal, July 2020

  • Pascoal, Tharick A.; Therriault, Joseph; Benedet, Andrea L.
  • Brain, Vol. 143, Issue 9
  • DOI: 10.1093/brain/awaa180

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
journal, April 2018

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
journal, October 2017

  • Bejanin, Alexandre; Schonhaut, Daniel R.; La Joie, Renaud
  • Brain, Vol. 140, Issue 12
  • DOI: 10.1093/brain/awx243

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
journal, September 2019

  • Jack, Clifford R.; Wiste, Heather J.; Botha, Hugo
  • Brain, Vol. 142, Issue 10
  • DOI: 10.1093/brain/awz268

Tau positron emission tomographic imaging in aging and early Alzheimer disease: Tau PET in Aging and Early AD
journal, December 2015

  • Johnson, Keith A.; Schultz, Aaron; Betensky, Rebecca A.
  • Annals of Neurology, Vol. 79, Issue 1
  • DOI: 10.1002/ana.24546

Pathological Tau Disrupts Ongoing Network Activity
journal, March 2015

Distinct tau PET patterns in atrophy‐defined subtypes of Alzheimer's disease
journal, January 2020

PET Imaging of Tau Deposition in the Aging Human Brain
journal, March 2016

Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer’s Disease Pathophysiology
journal, April 2021

The Central Role of Prognosis in Clinical Decision Making
journal, January 2012

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
journal, January 2019

Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
journal, October 2019

  • Smith, Ruben; Schöll, Michael; Leuzy, Antoine
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Issue 2
  • DOI: 10.1007/s00259-019-04496-0

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
journal, May 2014

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
journal, August 2019

Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer’s Disease Continuum
journal, August 2020

  • Iaccarino, Leonardo; La Joie, Renaud; Edwards, Lauren
  • Cerebral Cortex, Vol. 31, Issue 1
  • DOI: 10.1093/cercor/bhaa184

Biomarker Modeling of Alzheimer’s Disease
journal, December 2013

Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
journal, July 2020

Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study
journal, March 2019

Measuring the thickness of the human cerebral cortex from magnetic resonance images
journal, September 2000

  • Fischl, B.; Dale, A. M.
  • Proceedings of the National Academy of Sciences, Vol. 97, Issue 20
  • DOI: 10.1073/pnas.200033797

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
journal, August 2017

    Sort by:
    [ × clear filter / sort ]

    Similar Records in DOE PAGES and OSTI.GOV collections: